| scholarly article | Q13442814 |
| P50 | author | Andreas Bender | Q80079164 |
| P2093 | author name string | Thomas Klopstock | |
| P2860 | cites work | Creatine for amyotrophic lateral sclerosis/motor neuron disease | Q24202577 |
| The creatine kinase system and pleiotropic effects of creatine | Q24609852 | ||
| Emerging mechanisms of molecular pathology in ALS | Q28081239 | ||
| From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS | Q28206361 | ||
| Design, power, and interpretation of studies in the standard murine model of ALS | Q28268686 | ||
| The influence of creatine supplementation on the cognitive functioning of vegetarians and omnivores | Q28299561 | ||
| Creatine protects against excitoxicity in an in vitro model of neurodegeneration | Q28480553 | ||
| Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation | Q29547561 | ||
| Stages in the development of Parkinson's disease-related pathology | Q29615834 | ||
| Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial | Q30407589 | ||
| Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. | Q30440341 | ||
| Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate | Q30810394 | ||
| Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study | Q31878568 | ||
| Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial | Q48400110 | ||
| Distribution of the creatine transporter throughout the human brain reveals a spectrum of creatine transporter immunoreactivity. | Q48583660 | ||
| The role of creatine kinase in inhibition of mitochondrial permeability transition | Q48621172 | ||
| Brain creatine depletion in vegetarians? A cross-sectional ¹H-magnetic resonance spectroscopy (¹H-MRS) study | Q48832841 | ||
| An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria | Q54965159 | ||
| Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. | Q55032889 | ||
| Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats | Q33771249 | ||
| Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases | Q33837238 | ||
| Adverse effects of creatine supplementation: fact or fiction? | Q33918751 | ||
| Therapeutic use of creatine in brain or heart ischemia: available data and future perspectives | Q34089086 | ||
| Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease | Q34163054 | ||
| Caffeine and creatine use in sport | Q34166487 | ||
| A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis | Q34610044 | ||
| Role of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage | Q34954543 | ||
| A review of creatine supplementation in age-related diseases: more than a supplement for athletes | Q35005568 | ||
| Creatine protects against mitochondrial dysfunction associated with HIV-1 Tat-induced neuronal injury | Q35215063 | ||
| Mitochondrial dysfunction and amyotrophic lateral sclerosis | Q36350344 | ||
| Solving the lost in translation problem: improving the effectiveness of translational research | Q36487221 | ||
| Mitochondria in the aetiology and pathogenesis of Parkinson's disease | Q37037953 | ||
| The pathogenesis of cell death in Parkinson's disease--2007. | Q37050626 | ||
| Functions and effects of creatine in the central nervous system. | Q37172733 | ||
| PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease | Q37648786 | ||
| Creatine in mouse models of neurodegeneration and aging. | Q37851389 | ||
| Neuroprotective effects of creatine | Q37859313 | ||
| In sickness and in health: the widespread application of creatine supplementation. | Q37958749 | ||
| Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice | Q39125395 | ||
| Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice | Q40436889 | ||
| A clinical trial of creatine in ALS. | Q40469445 | ||
| The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease | Q41190386 | ||
| Immunohistochemical localisation of the creatine transporter in the rat brain. | Q42456481 | ||
| Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. | Q43572865 | ||
| Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease | Q43669934 | ||
| Direct antioxidant properties of creatine | Q43846466 | ||
| Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. | Q44296123 | ||
| A randomized sequential trial of creatine in amyotrophic lateral sclerosis | Q44383439 | ||
| Kinetics of creatine in blood and brain after intraperitoneal injection in the rat. | Q44438162 | ||
| Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial | Q44616594 | ||
| Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. | Q44674342 | ||
| Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis | Q44726519 | ||
| Creatine supplementation lowers brain glutamate levels in Huntington's disease | Q45239341 | ||
| Biochemical abnormalities and excitotoxicity in Huntington's disease brain. | Q45297145 | ||
| Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. | Q45299923 | ||
| In vivo neuroprotection by a creatine-derived compound: phosphocreatine-Mg-complex acetate. | Q45970604 | ||
| Long-term creatine supplementation is safe in aged patients with Parkinson disease. | Q46197864 | ||
| Protective effects of some creatine derivatives in brain tissue anoxia | Q46946975 | ||
| A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease | Q46947253 | ||
| Lost in translation: again, another failed neuroprotection trial. | Q46983561 | ||
| Acute renal failure in a young weight lifter taking multiple food supplements, including creatine monohydrate | Q47317205 | ||
| Creatine and cyclocreatine attenuate MPTP neurotoxicity | Q48223541 | ||
| Creatine supplementation enhances corticomotor excitability and cognitive performance during oxygen deprivation. | Q48354579 | ||
| P433 | issue | 8 | |
| P921 | main subject | neurodegeneration | Q1755122 |
| P304 | page(s) | 1929-1940 | |
| P577 | publication date | 2016-01-09 | |
| P1433 | published in | Amino Acids | Q15757015 |
| P1476 | title | Creatine for neuroprotection in neurodegenerative disease: end of story? | |
| P478 | volume | 48 |
| Q90164298 | Creatine as a Candidate to Prevent Statin Myopathy |
| Q55020079 | Creatine: a miserable life without it. |
| Q89747533 | Dietary creatine intake and depression risk among U.S. adults |
| Q92438333 | Effects of supplemental creatine and guanidinoacetic acid on spatial memory and the brain of weaned Yucatan miniature pigs |
| Q61808045 | Emergent Prophylactic, Reparative and Restorative Brain Interventions for Infants Born Preterm With Cerebral Palsy |
| Q48552818 | Guanidinoacetic acid versus creatine for improved brain and muscle creatine levels: a superiority pilot trial in healthy men. |
| Q64075331 | Impaired Redox Signaling in Huntington's Disease: Therapeutic Implications |
| Q33791877 | International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine |
| Q39031769 | Investigational agents for the management of Huntington's disease |
| Q91706744 | Investigations Into Bioenergetic Neuroprotection of Cone Photoreceptors: Relevance to Retinitis Pigmentosa |
| Q91428571 | Searching for a better formulation to enhance muscle bioenergetics: A randomized controlled trial of creatine nitrate plus creatinine vs. creatine nitrate vs. creatine monohydrate in healthy men |
| Q48221442 | Severe Hyperhomocysteinemia Decreases Creatine Kinase Activity and Causes Memory Impairment: Neuroprotective Role of Creatine |
| Q38764046 | Structural correlates of the creatine transporter function regulation: the undiscovered country |
| Q33760040 | The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials |
| Q38873820 | The effects of creatine supplementation on striatal neural progenitor cells depend on developmental stage |
Search more.